More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$41523566
EPS
-2.59
P/E ratio
--
Price to sales
0.43
Dividend yield
--
Beta
1.4769
Previous close
$8.91
Today's open
$9
Day's range
$8.83 - $9.58
52 week range
$4 - $10.20
show more
CEO
John Duke
Employees
339
Headquarters
Holliston, MA
Exchange
NASDAQ Capital Market
Shares outstanding
4573080
Issue type
Common Stock
Healthcare
Biotechnology & Life Sciences
Harvard Bioscience, Inc. (HBIO) Q3 2026 Earnings Call Transcript
Harvard Bioscience, Inc. (HBIO) Q3 2026 Earnings Call Transcript
Seeking Alpha • Nov 10, 2026

Harvard Bioscience Announces Third Quarter 2026 Financial Results
Third Quarter 2026 Revenue Growth of 8% Year Over Year to $22.2 Million Reaffirms Full Year 2026 Revenue Guidance of 3%-5% Year Over Year Growth HOLLISTON, Mass., Nov. 10, 2026 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company” or “Harvard Bioscience”) today announced financial results for the third quarter ended September 30, 2026.
GlobeNewsWire • Nov 10, 2026

Harvard Bioscience to Participate in the Canaccord Genuity MedTech, Diagnostics, and Digital Health and Services Forum
HOLLISTON, Mass., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) today announced that John Duke, President and Chief Executive Officer, and Mark Frost, Chief Financial Officer, will participate in Canaccord Genuity's MedTech, Diagnostics, and Digital Health and Services Forum on November 11th, 2026.
GlobeNewsWire • Nov 4, 2026

Harvard Bioscience Schedules Third Quarter 2026 Earnings Conference Call for November 10, 2026 at 8:00 AM ET
HOLLISTON, Mass., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce its financial results for the quarter ended September 30, 2026, before the market opens on November 10, 2026, and will hold a conference call to discuss the results at 8:00 a.m.
GlobeNewsWire • Oct 27, 2026

Harvard Bioscience Announces Creation of Scientific Advisory Board
HOLLISTON, Mass., Oct. 06, 2026 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) today announced the creation of its Scientific Advisory Board (SAB) to guide the Company's ongoing research, development, and new product roadmaps.
GlobeNewsWire • Oct 6, 2026

Harvard Bioscience, Inc. (HBIO) Q2 2026 Earnings Call Transcript
Harvard Bioscience, Inc. (HBIO) Q2 2026 Earnings Call Transcript
Seeking Alpha • Aug 11, 2026

Harvard Bioscience Schedules Second Quarter 2026 Earnings Conference Call for August 11, 2026 at 8:00 AM ET
HOLLISTON, Mass., July 28, 2026 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce its financial results for the quarter ended June 30, 2026, before the market opens on August 11, 2026, and will hold a conference call to discuss the results at 8:00 a.m.
GlobeNewsWire • Jul 28, 2026

Harvard Bioscience, Inc. (HBIO) Q1 2026 Earnings Call Transcript
Harvard Bioscience, Inc. (HBIO) Q1 2026 Earnings Call Transcript
Seeking Alpha • May 12, 2026

Harvard Bioscience Announces First Quarter 2026 Financial Results
First Quarter 2026 Revenues of $20.8M and Gross Margin of 59% Consolidation of Manufacturing Operations Progressing on Schedule Reaffirms Full Year 2026 Financial Guidance HOLLISTON, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company” or “Harvard Bioscience”) today announced financial results for the first quarter ended March 31, 2026.
GlobeNewsWire • May 12, 2026

Harvard Bioscience to Participate in Upcoming Investor Conferences
HOLLISTON, Mass., May 07, 2026 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) today announced Chief Executive Officer, John Duke and Chief Financial Officer, Mark Frost's participation in the following upcoming investor events.
GlobeNewsWire • May 7, 2026

¹ Disclosures

Open an M1 investment account to buy and sell Harvard Bioscience Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.